The pharmaceutical company Lundbeck will present new findings about migraine treatments at the European Academy of Neurology Congress 2026, held from June 27th to 30th in Geneva, Switzerland. They will showcase five presentations highlighting their current and future migraine prevention strategies, including new research on two different medications: eptinezumab and bocunebart.
The presentations on eptinezumab will focus on how it helps people with chronic migraine in ways beyond just reducing headache days. These include looking at how it affects the use of pain relief medications, mental health, and productivity at work.
A special late-breaking presentation on bocunebart will discuss how this investigational drug works by targeting a specific pathway in the body (called the PACAP pathway) that may help prevent migraines in people who haven’t responded well to other preventive treatments. Dr. Andrew Blumenfeld, a migraine specialist from Cedars Sinai in Los Angeles, will present the findings from the PROCEED study, saying: “This research adds to the growing scientific knowledge about how blocking the PACAP pathway could be a new way to help people with migraines who still struggle with their symptoms despite using other preventive treatments.”
Lundbeck will also share new results from two other studies on eptinezumab: the phase 3 SUNRISE trial and the phase 4 RESOLUTION trial. These results will look at how eptinezumab improves the overall burden of migraine, including its effects on daily functioning, mental health, and quality of life.
Three of the RESOLUTION study presentations will focus on adults with chronic migraine who also frequently overuse pain relief medications. These presentations will examine how migraine affects people across different European countries, how the use of pain relief medications changes over time, and how migraine impacts symptoms of anxiety and depression.
The SUNRISE study analysis will explore how eptinezumab helps improve workplace productivity and daily activities for people with migraine in Asia and Europe.
Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck, explained why these findings are important: “Migraine isn’t just about how many headache days a person has. For many, it affects their entire life, including work, relationships, and mental health. Unfortunately, these impacts aren’t always fully captured in standard ways of measuring treatment success. At this conference, we’re sharing data that better reflects the full impact of migraine and how our treatments can help. We’re also excited to share our progress in understanding how bocunebart, our investigational drug, works by targeting the PACAP pathway. Together, these efforts show Lundbeck’s dedication to improving brain health and finding better solutions for conditions like migraine where current treatments aren’t enough.”